Category

e-News Archive

IBTA e-News – July 2013

By e-News Archive

Hormone replacement therapy (HRT) and meningiomas: A Danish study of 924 women who had a meningioma has led to a claim that women on HRT have a 30 percent greater risk of getting a meningioma brain tumour but the findings have been dismissed by experts in women’s health. One consultant endocrinologist said that the risk might only represent one per 100,000 women per year and was “an absolutely trivial risk and of no clinical or biological importance”. Another expert said that with women who experience early menopause the benefits of HRT are likely to substantially outweigh the long-term risks without HRT, which included osteoporosis and cardiovascular diseases…

Read More

IBTA e-News – June 2013

By e-News Archive

ASCO and Avastin (bevacizumab): The results of two important clinical trials involving Avastin and glioblastoma were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago during 31 May – 4 June 2013. The two trials were RTOG 0825 (a double-blind placebo-controlled trial of Avastin in patients with newly-diagnosed GBM) and AVAglio (progression-free survival and health-related quality of life involving Avastin, temozolomide and radiotherapy in newly-diagnosed GBM)…

Read More

IBTA e-News – May 2013

By e-News Archive

Exciting development: A consortium of 28 brain tumour researchers from institutions around the world recently published a paper on a conceptually new treatment approach for relapsed glioblastoma (GBM). The approach is called “CUSP9” which stands for “Coordinated undermining of survival paths with nine repurposed drugs”…

Read More

IBTA e-News – April 2011

By e-News Archive

Bucharest conference: The IBTA had a display table at the EORTC/EANO “Trends in Central Nervous System Malignancies” conference which took place in Bucharest, Romania during 25-26 March 2011. An international faculty presented on topics at this well-attended meeting including, among others: “Glioblastoma – what are the next promising molecular targets?”…

Read More

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.